Q-omics provides the consensus-scored RPL22P21 profile across patient tissues and cancer cell-line models. RPL22P21 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPL22P21 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, RPL22P21 RNA expression shows 6,734 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, THCA, and GBM as cancer lineages where RPL22P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL22P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL22P21 survival associations across molecular data types. RPL22P21 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL22P21 RNA expression–survival associations across cancer types. High RPL22P21 expression shows unfavorable associations in SKCM, LIHC, THCA and LGG, but favorable associations in BLCA and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify BLCA as the clearest survival context for RPL22P21 RNA expression.
This table summarizes RPL22P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL22P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL22P21 shows lower tumor expression in THCA and BRCA and higher tumor expression in STAD and KIRC. The THCA box plot shows higher RPL22P21 RNA expression in normal versus tumor tissue (log2 FC = −0.076, t-test p < 0.001).
This table shows molecular features associated with RPL22P21 in patient tissues and cancer cell lines. In patient samples, RPL22P21 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
